Key Takeaways
- Concentrated 7-OH products are chemically enhanced and far stronger than kratom leaf, and the FDA has said 7-OH can be more potent than morphine.
- In October 2026 the DEA published a revised notice to temporarily place 7-OH above a set threshold in Schedule I, with an order expected no earlier than November 13, 2026.
- Texas law already limits 7-OH to 2 percent of a kratom product’s alkaloid fraction, bans synthetic 7-OH, and prohibits sales to anyone under 18.
- 7-OH withdrawal resembles opioid withdrawal, and treatment generally follows opioid use disorder principles, with research specific to 7-OH still early.
- Naloxone can reverse breathing problems caused by 7-OH, and families of someone using these products may want to keep it at home.
A few years ago, most people who ran into trouble with kratom were using powdered leaf or capsules. The calls clinicians get now often sound different: someone started with a small tablet or a flavored shot from a smoke shop, labeled 7-OH, and within weeks could not get through a morning without it. 7-OH kratom products are not the same thing as the leaf, and regulators have finally said so. This guide explains what 7-OH is, what federal and Texas officials have done about it, what dependence and withdrawal look like, and how treatment works. For the program itself, see our opioid addiction treatment in Houston page.
If you are looking for background on traditional kratom leaf, our earlier guide on kratom safety for Houston families covers that ground. This article focuses on the concentrated products that have grown into their own problem.
7-OH, defined: 7-hydroxymitragynine, an alkaloid found in only trace amounts in the kratom plant that binds strongly to the brain’s opioid receptors. Concentrated 7-OH products are made by chemically converting or synthesizing the compound, then selling it as tablets, gummies, shots, and similar products at far higher strengths than natural leaf contains.
How 7-OH Products Differ From Kratom Leaf
Kratom leaf contains many alkaloids, mostly mitragynine. 7-OH is present in the leaf, but only in small amounts. The U.S. Food and Drug Administration has said that 7-OH can be more potent than morphine, and the Texas Department of State Health Services (DSHS) has warned that semi-synthetic and synthetic products can contain 7-OH at concentrations of up to 98 percent.
That difference matters clinically. A person who has used kratom leaf for years may switch to a 7-OH product because it is convenient or because a clerk recommends it, and find that the effect, the tolerance, and the withdrawal all arrive faster and harder. Some products are fruit flavored or sold as candy, and the FDA has specifically raised concern that these may appeal to children and teens or be mislabeled as ordinary kratom.
- Leaf products: mostly mitragynine, with 7-OH in trace amounts
- Concentrated 7-OH products: chemically enhanced, sold in small, discreet doses, often in bright packaging
- Related compounds: newer products contain mitragynine pseudoindoxyl, sometimes sold as “pseudo,” which federal regulators have also moved to control
What Regulators Did About 7-OH, Federal and Texas
The regulatory picture has moved quickly. In July 2025 the FDA recommended that certain 7-OH products be controlled under the Controlled Substances Act, while saying it was not targeting natural kratom leaf. In September 2025 DSHS warned Texans not to use any 7-OH product. By late August 2025, the Texas Poison Center Network had received 192 reports involving kratom or 7-OH that year, compared with 107 in all of 2024; 19 involved concentrated 7-OH products, and 11 of those patients needed care at a health care facility.
Regulatory timeline
How the response to 7-OH unfolded
Key federal and Texas actions on concentrated 7-OH and related products, as of October 2026.
July 2025
The FDA recommends scheduling certain 7-OH products and says it is not focused on natural kratom leaf.
September 2025
Texas DSHS issues a public warning urging people not to use 7-OH products, citing a rise in poison center reports.
December 2025
The FDA announces a seizure of about 73,000 units of 7-OH products, valued at roughly $1 million.
August 2026
The DEA temporarily places mitragynine pseudoindoxyl and two related synthetic compounds in Schedule I.
October 2026
The DEA publishes a revised notice to temporarily schedule 7-OH and mitragynine pseudoindoxyl above a set threshold, with an order expected no earlier than November 13, 2026.
Summary of public notices from the FDA, the DEA, and Texas DSHS. Regulatory status can change; check current federal and state sources for the latest.
The October 2026 DEA notice replaced a July 2026 proposal that used a lower threshold. Under the revised notice, products would fall under Schedule I control if they contain more than 1 milligram of 7-OH or mitragynine pseudoindoxyl per gram (or per milliliter for liquids), or if the ratio of mitragynine to those compounds is below 100 to 1. A temporary order lasts two years and can be extended by one. The DEA has said its action does not override stricter state laws.
In Texas, the Kratom Consumer Protection Act already bars products in which 7-OH makes up more than 2 percent of the alkaloid fraction, bars products containing synthetic alkaloids including synthetic 7-OH, and prohibits sales to anyone under 18. A 2025 bill that would have tightened those limits passed the Texas Senate but did not become law. None of this is legal advice; it is offered so families understand why these products are under so much scrutiny.
7-OH Dependence: Why It Builds So Fast
Because 7-OH acts on opioid receptors, the brain adapts to it the way it adapts to other opioids. Tolerance builds, so the same amount does less. Doses creep up or get closer together. Many people describe dosing on a clock, not because they want to feel high, but because they feel sick without it.
The people we see are often surprised by how quickly this happened. Many started kratom or 7-OH for reasons that made sense at the time: back pain, low energy, anxiety, or an attempt to get off prescription opioids. The FDA has noted that neither kratom nor 7-OH has an approved medical use, so there is no standard dose, no reliable labeling, and no medical oversight built into how these products are bought and used.
Signs that use has become dependence include:
- Needing more product, or stronger product, to get the same effect
- Feeling restless, achy, or sick within hours of the last dose
- Spending more money than planned, or hiding purchases
- Trying to cut back and not being able to
- Using alongside alcohol, benzodiazepines, or other sedatives
For Families and Loved Ones
Worried about 7-OH use?
A confidential assessment can clarify whether withdrawal needs medical support and what treatment should come next.
What 7-OH Withdrawal Feels Like
Withdrawal from concentrated 7-OH looks much like opioid withdrawal: anxiety, restlessness, muscle aches, sweating, runny nose, yawning, stomach cramps, diarrhea, and poor sleep. It is rarely life threatening on its own in otherwise healthy adults, but it is intensely uncomfortable, and that discomfort is the main reason people go back to using. Withdrawal becomes more complicated when someone is also using alcohol or benzodiazepines, has significant medical problems, or is pregnant.
Texas DSHS lists serious effects linked to 7-OH, including agitation, confusion, rapid heart rate, high blood pressure, seizures, trouble breathing, and loss of consciousness. Because 7-OH is an opioid-acting substance, naloxone can reverse respiratory depression, and DSHS has advised clinicians to use it. Families who have a loved one using 7-OH may want to keep naloxone at home and know how to use it.
Treatment for 7-OH Kratom Dependence
Because 7-OH works like an opioid, clinicians generally approach dependence the way they approach opioid use disorder. Research specific to 7-OH is still early, and much of what is published consists of case reports, so honest treatment starts with a careful assessment rather than a one-size plan.
For many people, care includes:
- A clinical assessment of how much, how often, and what else is being used, including alcohol and sedatives
- A plan for withdrawal: some people can be managed as outpatients, while others need a medically supervised detox setting
- Consideration of medication for opioid use disorder; case reports describe buprenorphine being used for kratom and 7-OH dependence, and decisions are made individually with a prescriber
- Therapy that addresses why use started, whether that is chronic pain, anxiety, depression, or a previous opioid problem
- Family involvement, since loved ones often notice the change before the person using does
When 7-OH use started as a way to manage pain or mood, treating only the substance leaves the original problem in place. That is why dual diagnosis care often matters as much as the medication plan. For people whose 7-OH use followed prescription opioids, our guide to opioid and prescription drug addiction treatment covers related ground.
How Heights Can Help
Heights Behavioral Health is an outpatient practice in the Houston Heights. We do not provide detox, but we assess withdrawal risk up front, coordinate a referral when supervised withdrawal is needed, and have outpatient care ready to begin as soon as it is appropriate. Our substance use treatment includes partial hospitalization, intensive outpatient programming with evening options, individual and group therapy, family programming, and medication-assisted treatment with buprenorphine or naltrexone where it fits.
Crisis notice. If someone is unresponsive, breathing slowly, or cannot be woken, call 911 immediately and give naloxone if you have it. For questions about a possible poisoning, call Poison Help at 1-800-222-1222. Heights Behavioral Health provides scheduled outpatient care and is not an emergency or detox service. If you are in crisis, call or text 988.
Frequently Asked Questions
Is 7-OH the same as kratom?
No. 7-OH is one alkaloid that occurs in trace amounts in kratom leaf. Concentrated 7-OH products are chemically enhanced to contain far more of it, which makes them much stronger and more likely to cause dependence than traditional leaf products.
Is 7-OH illegal now?
As of October 2026, the DEA has published a revised notice to temporarily place 7-OH above a set threshold in Schedule I, with an order expected no earlier than November 13, 2026. Texas law already limits 7-OH in kratom products and bans synthetic 7-OH. Laws are changing quickly, so check current sources.
Can you detox from 7-OH at home?
Some people can, with medical guidance, if they are not using other sedatives and have no major health problems. Others need a supervised setting. A clinical assessment before stopping is the safest way to decide.
Does naloxone work on 7-OH?
Texas health officials have advised clinicians to give naloxone to reverse breathing problems caused by 7-OH, because it acts on opioid receptors. Always call 911 as well, since other substances may be involved.
Sources
- U.S. Food and Drug Administration. FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers. fda.gov
- Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I. federalregister.gov
- Texas Department of State Health Services. Public Health Officials Warn People Not to Use 7-OH Products. dshs.texas.gov
- Texas Department of State Health Services. Kratom Processor and Retailer Requirements. dshs.texas.gov
- U.S. Food and Drug Administration. FDA Seizes 7-OH Opioids to Protect American Consumers. fda.gov
Written and Reviewed by Licensed Clinicians
Joni Ogle is a Licensed Clinical Social Worker (LCSW) and Certified Sex Addiction Therapist (CSAT) with over 37 years of clinical experience in mental health and addiction recovery, dual diagnosis treatment, behavioral addictions, and family intervention. She is the founder of Heights Behavioral Health and Heights Mentoring in Houston, Texas, where she leads a team of licensed clinicians.
Texas LCSW #37376 · Verify license
Deborah Darnell-Drake, LCSW-S, ACSW, LMFT is the Chief Clinical Officer at Heights Behavioral Health and a clinical reviewer. With more than five decades of experience in mental health and substance use disorder treatment, Deborah specializes in addiction, co-occurring mental health conditions, family dynamics, and behavioral addictions including gambling and technology addiction.
Texas LCSW-S #14508 · LMFT #1125 · Verify license
Start a Confidential Conversation
One confidential message connects you with our admissions team and a clear next step. Prefer to talk now? Call (877) 549-5102.
